Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Camrelizumab - Jiangsu Hengrui Medicine

Next Previous
Drug Profile

Camrelizumab - Jiangsu Hengrui Medicine

Alternative Names: AiRuiKa; Carbarizumab; Carrizumab; HR-301210; INCSHR-1210; SHR 1210; SHR01210

Latest Information Update: 05 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Developer Chinese PLA General Hospital; CrystalGenomics; Fudan University; Fudan University Shanghai Cancer Center; Guangzhou Institute of Respiratory Disease; Hangzhou Cancer Hospital; Henan Cancer Hospital; Incyte Corporation; Jiangsu Hengrui Medicine Co.; Nanjing Medical University; Peking University People's Hospital; Sun Yat-Sen University; Suzhou Suncadia Biopharmaceuticals; The First Affiliated Hospital of Zhengzhou University; Tianjin Medical University Cancer Institute and Hospital; West China Hospital Sichuan University
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hodgkin's disease; Liver cancer; Nasopharyngeal cancer; Non-small cell lung cancer; Oesophageal cancer
  • Phase III Cervical cancer; Gastric cancer; Triple negative breast cancer
  • Phase II Acral lentiginous melanoma; Biliary cancer; Breast cancer; Cholangiocarcinoma; Colorectal cancer; Endometrial cancer; Fallopian tube cancer; Gastrointestinal cancer; Glioblastoma; HER2 negative breast cancer; Lung cancer; Malignant fibrous histiocytoma; Malignant melanoma; Osteosarcoma; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Renal cell carcinoma; Small cell lung cancer; Soft tissue sarcoma; Solid tumours; Squamous cell cancer; Thyroid cancer; Urogenital cancer; Uterine cancer
  • Phase I/II Bladder cancer; Diffuse large B cell lymphoma

Most Recent Events

  • 05 Mar 2024 Jiangsu HengRui Medicine completes a phase III trial in Triple-negative-breast cancer (Combination therapy, Early-stage disease, Late-stage disease, In adults, In the elderly, Neoadjuvant therapy) in China (IV) (NCT04613674)
  • 23 Feb 2024 363273: No updates; hospital sponsored trial of well launched drug hence not covered; deal between hospital and company not found
  • 18 Jan 2024 Adverse events data from a phase III CARES 310 trial in Liver cancer presented at the 2024 Gastrointestinal Cancers Symposium (ASCO-GCS-2024)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top